The SENTIS analysis evaluates the genes involved in hereditary cancers of women and men. At Procrea Fertility, there are two possible analysis options:
-Panel of 2 genes: BRCA1 and BRCA2
-Panel of 21 genes including BRCA1 and BRCA2
The genes in panels 1 and 2 have been implicated in increasing the risk of cancer, although the risk varies with each gene. There is currently no test that can detect all the mutations associated with an increased risk of developing cancer and no test can analyze all the genetic causes of cancer, since not all causes are yet known. Environmental factors and lifestyles can also contribute to cancer development.
Knowing that I am carrying a mutation in one or more of the genes analyzed, could help me and my health professional make informed medical decisions to prevent or detect cancers at an early stage and therefore possibly easier to treat. In addition, my results could provide interesting information to my biological family.
The SentisTM Breast and Ovarian Cancer Screening Test offers 2 different options:
- 1A screening panel of 2 genes: BRCA1 and BRCA2
- 2A screening panel of 21 genes including BRCA1 / BRCA2 and 19 other genetic mutations that have been associated with cancer.
Sentis analysis for hereditary cancers: clinical study > 7000 samples; sensitivity, specificity > 99% / Hereditary Cancer tests: > 7000 clinical samples tested; sensitivity, specificity > 99%.
*Source : NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health. BRCA1 and BRCA2 Hereditary Breast and Ovarian Cancer. 2016 edition.
Source: Am J Hum Genet. 2003 May; 72(5): 1117-1130. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: A combined analysis of 22 studies.